ALGS:NSD-Aligos Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.20

Change

-0.18 (-1.10)%

Market Cap

USD 0.70B

Volume

0.12M

Avg Analyst Target

USD 29.00 (+79.01%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: One Corporate Drive, South San Francisco, CA, United States, 94080

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.86 (-1.41%)

USD139.56B 40.85 31.63
BNTX BioNTech SE

-13.62 (-4.66%)

USD70.91B 16.26 11.68
REGN Regeneron Pharmaceuticals Inc

-2.55 (-0.43%)

USD62.24B 10.69 7.94
VRTX Vertex Pharmaceuticals Incorpo..

-3.13 (-1.70%)

USD47.75B 24.27 16.15
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-16.37 (-4.27%)

USD35.80B N/A N/A
SGEN Seagen Inc

-3.09 (-1.74%)

USD32.33B 55.44 43.27
GMAB Genmab A/S

-0.46 (-1.01%)

USD30.35B 77.92 9.04
ALNY Alnylam Pharmaceuticals Inc

-6.55 (-3.31%)

USD23.50B N/A N/A
RPRX Royalty Pharma plc

-0.93 (-2.46%)

USD22.91B 30.56 12.22

ETFs Containing ALGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.41% 28% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.41% 28% F 12% F
Trailing 12 Months  
Capital Gain 7.00% 59% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.00% 59% F 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.10% 33% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.10% 32% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 1.00% 100% A+ 99% A+
Risk Adjusted Return 9.73% 39% F 26% F
Market Capitalization 0.70B 67% D+ 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.97 46% F 35% F
Price / Cash Flow Ratio -9.40 57% F 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -101.43% 25% F 18% F
Return on Invested Capital -126.32% 12% F 5% F
Return on Assets -44.26% 16% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.31 36% F 21% F
Short Percent 9.94% 20% F 17% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector